GSK1024850A (SynflorixTM) — Competitive Intelligence Brief

GSK1024850A (SynflorixTM) (GSK1024850A (SynflorixTM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal conjugate vaccine. Area: Immunology / Infectious Disease.

marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) Immunology / Infectious Disease Biologic

Target snapshot

GSK1024850A (SynflorixTM) (GSK1024850A (SynflorixTM)) — GlaxoSmithKline. Synflorix is a pneumococcal conjugate vaccine that stimulates immune responses against multiple serotypes of Streptococcus pneumoniae.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK1024850A (SynflorixTM) TARGET	GSK1024850A (SynflorixTM)	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Prevnar13	Prevnar13	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Streptococcus pneumoniae serotype 3	Streptococcus pneumoniae serotype 3	University of Oxford	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae serotype 3 capsular polysaccharide
PCV10 full dose	PCV10 full dose	Epicentre	marketed	Pneumococcal conjugate vaccine
PCV13 alone	PCV13 alone	Korea University Guro Hospital	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsule (13 serotypes)
Prevnar 20 vaccine	Prevnar 20 vaccine	Sanofi	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide capsules (20 serotypes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Pneumococcal conjugate vaccine class)

1. GlaxoSmithKline · 12 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Korea University Guro Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. Papua New Guinea Institute of Medical Research · 1 drug in this class
6. Pfizer Inc. · 1 drug in this class
7. Sanofi · 1 drug in this class
8. University of Minnesota · 1 drug in this class
9. University of Oxford · 1 drug in this class
10. Vabiotech · 1 drug in this class